Allgenesis Biotherapeutics Inc
Allgenesis is a privately owned, clinical stage, biopharmaceutical company based in Taipei City, Taiwan. Its mission is to find solutions for major eye diseases affecting millions worldwide and to establish a world-renowned biopharmaceutical business in Taiwan by inventing and developing novel medicines for the global market.
Industries
Nr. of Employees
small (1-50)
Allgenesis Biotherapeutics Inc
Products
AG-73305
Bispecific biologic combining anti-VEGF activity and integrin/disintegrin-based activity formulated as an intravitreal therapeutic for retinal diseases.
AG-80308
A formyl peptide receptor (FPR) agonist developed for treatment of dry eye and ocular inflammation; noted as an in-licensed clinical candidate.
AG-86893
A tyrosine kinase inhibitor developed as a topical ophthalmic candidate for pterygium; referenced as a 505(b)(2) pathway program.
Disintegrin platform
A biologic platform using disintegrin-based mechanisms intended to modulate integrin pathways for retinal disease indications.
AG-73305
Bispecific biologic combining anti-VEGF activity and integrin/disintegrin-based activity formulated as an intravitreal therapeutic for retinal diseases.
AG-80308
A formyl peptide receptor (FPR) agonist developed for treatment of dry eye and ocular inflammation; noted as an in-licensed clinical candidate.
AG-86893
A tyrosine kinase inhibitor developed as a topical ophthalmic candidate for pterygium; referenced as a 505(b)(2) pathway program.
Disintegrin platform
A biologic platform using disintegrin-based mechanisms intended to modulate integrin pathways for retinal disease indications.
Services
Clinical development services for ophthalmic therapeutics
Design and conduct of early‑phase ophthalmology clinical studies including protocol development, site management and patient recruitment.
Preclinical and nonclinical development support
Design and oversight of nonclinical pharmacology, PK, toxicology and ocular pathology studies to support IND-enabling packages.
CMC, analytical and formulation development
Analytical method development, formulation and process development support for biologic drug substance and drug product.
Regulatory strategy and interactions
Regulatory planning and preparation for health‑authority meetings and submissions (Pre‑IND/IND and related interactions).
Licensing and partnering evaluation
Assessment and integration of in‑licensed candidates into the company pipeline and engagement in business development activities.
Clinical development services for ophthalmic therapeutics
Design and conduct of early‑phase ophthalmology clinical studies including protocol development, site management and patient recruitment.
Preclinical and nonclinical development support
Design and oversight of nonclinical pharmacology, PK, toxicology and ocular pathology studies to support IND-enabling packages.
CMC, analytical and formulation development
Analytical method development, formulation and process development support for biologic drug substance and drug product.
Regulatory strategy and interactions
Regulatory planning and preparation for health‑authority meetings and submissions (Pre‑IND/IND and related interactions).
Licensing and partnering evaluation
Assessment and integration of in‑licensed candidates into the company pipeline and engagement in business development activities.
Expertise Areas
- Clinical trial management (ophthalmology)
- Ophthalmic drug discovery and preclinical development
- Biologic therapeutics development
- Small-molecule ophthalmic development
Key Technologies
- Bispecific biologics (Fc-fusion)
- Disintegrin-based biologic platforms
- Small-molecule tyrosine kinase inhibitors
- Formyl peptide receptor (FPR) agonists